In a groundbreaking development for animal health and the poultry industry, Vaxxinova US proudly announces the approval of a live Avian metapneumovirus vaccine, Vaxxon® SHS, for importation into the U.S. market by the United States Department of Agriculture (USDA). This significant milestone in the fight against Avian metapneumovirus (aMPV) marks a momentous occasion for the industry.
Vaxxon® SHS is a lyophilized live attenuated metapneumovirus vaccine designed to protect against Swollen Head Syndrome in poultry. Developed by Vaxxinova Italy, this innovative vaccine has undergone rigorous testing and evaluation to demonstrate exceptional efficacy and safety.
Brian Harberts, Managing Director and spokesperson for Vaxxinova, expressed pride in the USDA’s approval, calling it a testament to the company’s commitment to advancing animal health and meeting customer needs. He highlighted the devastating impact of aMPV on the U.S. turkey and poultry industry and emphasized the collaborative effort with industry organizations, poultry producers, and the USDA that led to this milestone. Vaxxinova US can now offer the same proven vaccine to the U.S. market that has been successfully used in Europe for over twenty years.
Dr. Dan Domingo, Senior Poultry Technical Service Veterinarian at Vaxxinova, explained the importance of using live attenuated virus vaccines followed by inactivated vaccines to control Avian Metapneumovirus. He noted that live vaccines can stimulate both systemic and local immunity in the respiratory tract, providing an effective defense against the virus. Domingo also highlighted the role of live vaccines in priming birds for the use of inactivated vaccines, further enhancing protection.
The collaboration between Vaxxinova, the USDA, international colleagues, and key stakeholders has been crucial in bringing this innovative solution to the U.S. market. Distribution of Vaxxon® SHS Live vaccine is set to begin in early 2025, with a focus on meeting the needs of the turkey industry. Additionally, Vaxxinova will offer an inactivated autogenous aMPV vaccine for U.S. producers, providing a comprehensive solution that combines live vaccine priming with inactivated boosters.
The approval of Vaxxon® SHS represents a significant step forward in combating Avian metapneumovirus and protecting poultry health. By harnessing the power of innovative vaccine technology and collaborative partnerships, Vaxxinova is leading the way in addressing the challenges facing the poultry industry. The availability of this advanced vaccine in the U.S. market will provide poultry producers with a valuable tool in safeguarding their flocks and ensuring the continued health and well-being of their animals.